January 13, 2023
1 minute read
LinusBio raises over $16 million in Series A funding to deliver technology that combines genomics, environment and biological responses to help diagnose and monitor progression of disorders such as ALS and autism announced that it had procured
The new platform also aims to improve clinical trials by providing data comparable to liquid biopsies or blood samples from a single hair, according to a LinusBio release.
LinusBio, a company specializing in high-precision exposome sequencing, announced it has raised $16 million to develop a new platform to aid in the diagnosis and treatment of various diseases. Source: Adobe Stock
The company will initially focus on neurological diseases and aims to use the platform to identify novel compounds for health conditions where genomic biomarkers have had limited success so far.
“Our mission is simple: to improve outcomes for people and families suffering from complex health conditions.” Mannish Arora doctorate, LinusBio’s CEO and co-founder said in a release. “We are proud to launch the LinusBio platform to meet the tremendous need for better, faster and more comprehensive diagnostics and treatments for a wide variety of conditions and diseases.”
According to the release, the company’s program pipeline also includes advanced biomarkers for oncology, gastroenterology and psychiatric disorders.
